Standardized methods for the production of high specific-activity zirconium-89

• Published in: Nuclear medicine and biology Vol. 36; no. 7; pp. 729 - 739
• Main Authors: Holland, Jason P, Sheh, Yiauchung, Lewis, Jason S
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.10.2009
• Subjects: Animals; Benchmarking; Chelating Agents - chemistry; Cyclotron targetry; Cyclotrons; Deferoxamine - chemistry; Desferrioxamine; Humans; Hydroxamates; Hydroxamic Acids - chemistry; Ligands; Male; Mice; Positron emission tomography; Radioisotopes; Radiology; Radiopharmaceuticals; Reproducibility of Results; Zirconium - chemistry; Zirconium-89; Zirconium-89; Desferrioxamine; Radiopharmaceuticals; Positron emission tomography; Cyclotron targetry; Hydroxamates
• ISSN: 0969-8051; 1872-9614
• DOI: 10.1016/j.nucmedbio.2009.05.007

Abstract Zirconium-89 is an attractive metallo-radionuclide for use in immuno-PET due to favorable decay characteristics. Standardized methods for the routine production and isolation of high-purity and high-specific-activity89 Zr using a small cyclotron are reported. Optimized cyclotron conditions reveal high average yields of 1.52±0.11 mCi/μA·h at a proton beam energy of 15 MeV and current of 15 μA using a solid, commercially available89 Y-foil target (0.1 mm, 100% natural abundance).89 Zr was isolated in high radionuclidic and radiochemical purity (>99.99%) as [89 Zr]Zr-oxalate by using a solid-phase hydroxamate resin with >99.5% recovery of the radioactivity. The effective specific-activity of89 Zr was found to be in the range 5.28–13.43 mCi/μg (470–1195 Ci/mmol) of zirconium. New methods for the facile production of [89 Zr]Zr-chloride are reported. Radiolabeling studies using the trihydroxamate ligand desferrioxamine B (DFO) gave 100% radiochemical yields in <15 min at room temperature, and in vitro stability measurements confirmed that [89 Zr]Zr-DFO is stable with respect to ligand dissociation in human serum for >7 days. Small-animal positron emission tomography (PET) imaging studies have demonstrated that free89 Zr(IV) ions administered as [89 Zr]Zr-chloride accumulate in the liver, whilst [89 Zr]Zr-DFO is excreted rapidly via the kidneys within <20 min. These results have important implication for the analysis of immuno-PET imaging of89 Zr-labeled monoclonal antibodies. The detailed methods described can be easily translated to other radiochemistry facilities and will facilitate the use of89 Zr in both basic science and clinical investigations.